Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Bavarian Nordic Enters Clinical Trials With Prostate Cancer Vaccine
June 17th, 2008
Bavarian Nordic's subsidiary, BN ImmunoTherapeutics has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer. A Phase I/II safety and tolerability study in 18 male patients with non-metastatic as well as hormone-insensitive prostate cancer has begun enrolment in the US. Secondary objectives of the trial include examining the ability of the vaccine to induce prostate antigen-specific immune responses, as well as clinical anti-tumour activity. Preliminary data is expected during second half year 2009. The therapeutic vaccine, based on the Company's MVA-BN(R) technology, is designed to generate cellular...
Source: Cancer Weekly (2008-06-17)
|
